SAPPHIRE:结直肠癌患者六周期mFOLFOX6联合帕尼单抗后计划停用或持续奥沙利铂的随机II期研究
SAPPHIRE研究纳入化疗初治的RAS野生型转移性结直肠癌患者,先接受六周期mFOLFOX6联合帕尼单抗诱导治疗,未进展者随机分为继续mFOLFOX6联合帕尼单抗组(A组)或5-FU/LV联合帕尼单抗组(B组)。主要终点为随机化后9个月无进展生存率,两组分别为46.4%和47.4%,疗效相似,但B组≥2级周围神经病变发生率(9.3%)低于A组(35.7%)。
要点
- 六周期诱导后停用奥沙利铂,9个月PFS率与持续使用相似。
- 停用奥沙利铂组≥2级周围神经病变发生率更低(9.3% vs 35.7%)。
- 该策略可作为RAS野生型mCRC患者的一种潜在治疗选择。
核心结论
- 六周期mFOLFOX6联合帕尼单抗后计划停用奥沙利铂,在维持疗效的同时减少奥沙利铂相关周围神经病变。
研究设计与样本
- 随机II期研究,纳入化疗初治的RAS野生型转移性结直肠癌患者,年龄≥20岁,先接受六周期mFOLFOX6联合帕尼单抗诱导治疗。
- 诱导治疗后未进展者随机分为A组(继续mFOLFOX6联合帕尼单抗,n=56)和B组(5-FU/LV联合帕尼单抗,n=57),共164例入组,113例随机。
主要发现
- 随机化后中位随访19.6个月,A组9个月PFS率为46.4%(80%CI 38.1-54.9),中位PFS为9.1个月(95%CI 8.6-11.1)。
- B组9个月PFS率为47.4%(80%CI 39.1-55.8),中位PFS为9.3个月(95%CI 6.0-13.0)。
- 两组缓解率、总生存和无治疗失败时间相似。
- B组≥2级周围神经病变发生率为9.3%,低于A组的35.7%。
关键数值与推荐
- 主要终点为随机化后9个月无进展生存率,A组46.4%(80%CI 38.1-54.9),B组47.4%(80%CI 39.1-55.8)。
- B组≥2级周围神经病变发生率为9.3%,A组为35.7%。
临床怎么用
- 对于完成六周期mFOLFOX6联合帕尼单抗诱导治疗且未进展的RAS野生型mCRC患者,可考虑计划停用奥沙利铂以降低周围神经病变风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (FOLFOX) plus panitumumab therapy is a commonly used first-line chemotherapy for metastatic colorectal cancer (mCRC). However, the long-term administration of oxaliplatin is associated with peripheral neuropathy (PN). We investigated whether the planned discontinuation of oxaliplatin after FOLFOX plus panitumumab therapy can maintain efficacy and reduce PN incidence. PATIENTS AND METHODS: Chemotherapy-naive patients with RAS wild-type mCRC, aged ≥20 years, were enrolled and received six cycles of modified FOLFOX6 (mFOLFOX6) plus panitumumab as induction therapy. Patients who completed induction therapy without progression were randomised to mFOLFOX6 plus panitumumab (group A) or to 5-FU/LV plus panitumumab (group B). The primary end-point was the progression-free survival (PFS) rate at 9 months after randomisation. The secondary end-points were PFS, overall survival (OS), time to treatment failure (TTF), response rate (RR) and safety. RESULTS: In total, 164 patients were enrolled; of whom, 113 patients were then randomised (group A, n = 56; group B, n = 57). The median follow-up after randomisation was 19.6 months. The PFS rates at 9 months and median PFS were 46.4% (80% confidence interval [CI], 38.1-54.9) and 9.1 months (95% CI, 8.6-11.1) in group A, compared with 47.4% (80% CI, 39.1-55.8) and 9.3 months (95% CI, 6.0-13.0) in group B, respectively. RR, OS and TTF were also similar in both groups. Grade ≥2 PN incidence was lower in group B (9.3%) than in group A (35.7%). CONCLUSION: Planned discontinuation of oxaliplatin after six cycles of mFOLFOX6 plus panitumumab is a potential treatment option in patients with mCRC, achieving similar efficacy while reducing oxaliplatin-associated PN compared with mFOLFOX6 plus panitumumab. TRIAL REGISTRATION NUMBER: NCT02337946.
引用
- Munemoto Y, Nakamura M, Takahashi M, et al. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer. Eur J Cancer. 2019. PMID: 31445198. doi:10.1016/j.ejca.2019.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。